Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination…
– 83% composite complete response rate in newly diagnosed unfit AML patients with RARA gene overexpression –
- Initial safety and clinical activity profile of the triplet regimen supports advancing SELECT-AML-1 into the randomized…